Meeting
2019 ASCO Annual Meeting
Phase I study of KN035, the first subcutaneously administered, novel fusion anti-PD-L1 antibody in patients with advanced solid tumors in China.
Authors
Jian-Ming Xu
307 Hospital of PLA, Beijing, China
Jian-Ming Xu , Shukui Qin , Yun Zhang , Yaoyue Zhang , Ru Jia , Rongrui Liu , Gairong Zhang , Chuanhua Zhao , Ni Lu , Huilong Liu , Wenlian Xu , Meng Fu , Walt Cao , Haolan Lu , David Liu , Ruiping Dong , Xiaoxiao Wang , Pilin Wang , Ting Xu , John Gong
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Immunotherapy and Tumor Immunobiology
Track
Developmental Therapeutics—Immunotherapy
Sub Track
New Targets and New Technologies (IO)
Clinical Trial Registration Number
NCT03101488
Citation
J Clin Oncol 37, 2019 (suppl; abstr 2608)
DOI
10.1200/JCO.2019.37.15_suppl.2608
Abstract #
2608
Poster Bd #
252
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A first-in-human, phase 1 study of the SHP2 inhibitor PF-07284892 as monotherapy and in combination with different targeted therapies in oncogene-driven, treatment-resistant solid tumors.
First Author: Alexander E. Drilon
Poster
2022 ASCO Annual Meeting
Phase I dose-escalation study of IBI351 (GFH925) monotherapy in patients with advanced solid tumors.
First Author: Qing Zhou
Poster
2022 ASCO Annual Meeting
NCI 9938: Phase I clinical trial of ATR inhibitor berzosertib (M6620, VX-970) in combination with irinotecan in patients with advanced solid tumors.
First Author: Liza C Villaruz
Poster
2022 ASCO Annual Meeting
First-in-human, phase 1, open-label, dose-escalation, dose-expansion study of ADCT-901 as monotherapy in patients with select advanced solid tumors.
First Author: R. Donald Harvey